Replies to post #8412 on ANI Pharmaceuticals (ANIP)

[jeffqdhsr]

I recall Art P said he would not place a firm earning guidance because of product launches like Asprin that may impact same , I’d have to go back to Presentation but I think that one product would share in 100 Mil market only one Comp , if that’s true then we’re looking at poss 250 Mil sales ?

And Corti is the wild card for me , a ok by FDA launches ANI into a whole different MC , I spoke to Art about potential , the number is poss 200 Mil added to net revenue in my business we call that a play with #s , if true were talking about adding on a substantial gross , IMO 600-800 Mil that could have been the trade off for not pursuing Libigel and his instinct s may be correct !

JMHO